Mirati Spies ‘First-In-Class’ Chance For KRAS Inhibitor In Pancreatic Cancer
Adds To Colorectal Cancer Opportunity
While chasing Amgen’s Lumakras in NSCLC, Mirati looks to now have an edge in two other tumor types.
You may also be interested in...
With Vida Ventures and Leaps by Bayer leading the round, Affini-T raises $175m to advance its KRAS-targeted T-cell therapies into the clinic and add technological capabilities.
The firm’s first-in-class KRAS inhibitor has shown lower objective response rates than Mirati’s rival candidate in a Phase I/II pancreatic cancer study, but experts note that its lung cancer opportunity, where Amgen can build up a considerable lead, is larger.
As the first CRISPR-based therapies draw closer to approval, the Flagship-backed biotech believes its gene writing tech is the ‘definitive’ genetic medicine platform.